Amara Raja Energy & Mobility Limited — Others, 30-05-2025: Copy of Newspaper Publication

Glenmark Pharmaceuticals is advancing licensing talks for its ISB 2001 trispecific antibody targeting multiple myeloma, which holds orphan drug status and FDA fast-track designation, signaling a potential boost to its pipeline. The company is gearing up to manufacture semaglutide for India as the drug nears patent expiry. Glenmark will exit clinical supply manufacturing at its Switzerland site, shifting production to global contract manufacturers to support pipeline expansion. Arvind plans ₹475 Cr capex for FY26 to raise garment output from 40 to 60 million units, leveraging the India-UK Free Trade Agreement to diversify beyond the US market amid strong US demand. Mapmygenome acquired Microbiome Insights, gaining a CAP-accredited US lab to enhance its AI-driven genomics and microbiome testing, accelerating entry into the North American personalized health market.